Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)



Status:Recruiting
Conditions:Prostate Cancer, Chronic Pain
Therapuetic Areas:Musculoskeletal, Oncology
Healthy:No
Age Range:18 - 85
Updated:4/21/2016
Start Date:September 2015
End Date:March 2017
Contact:Richard Urman, MD
Email:urmanr@gmail.com
Phone:6177328222

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV) in Patients Undergoing Robotic-assisted Laparoscopic Prostatectomy

To examine pharmacoeconomics of IV acetaminophen (Ofirmev). Specifically, to examine its
potential to improve hospital efficiency and patient outcomes. The investigators compare the
addition of IV acetaminophen versus placebo on postoperative PACU recovery times, inpatient
hospital length of stay (LOS), patient satisfaction scores, postoperative pain scores,
consumption of opiates as rescue agents and side effects, and costs associated with
postoperative medications among patients undergoing robotic-assisted laparoscopic
prostatectomy (RALP).


Inclusion Criteria:

- Patients undergoing robotic-assisted laparoscopic prostatectomy

- ≥18 years old males

- ASA class 1-4

Exclusion Criteria:

- Chronic opiate use

- Liver disease (known history of hepatitis B or C, cirrhosis, nonalcoholic
steatohepatitis, history of alcoholism, ALT/AST greater than 3 times upper limit of
normal in the past 3 months)

- Allergy/hypersensitivity to acetaminophen

- Patients with baseline dementia

- Chronic diathesis

- Chronic kidney disease
We found this trial at
1
site
Brigham and Women's Hosp
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Phone: 617-732-8222
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials